It was the best of times, it was the worst of times... --Charles Dickens
These words sum up the state of Alzheimer’s disease (AD) research, specifically therapy development, over the last few years.
On the one hand, the budget climate and dismal therapeutic results cloud the future. On the other hand, there are tremendous opportunities presented by the U.S. National Plan to Address Alzheimer’s Disease and by the emergence of systems and precision medicine. These could transform AD research and drug development.
Why hold another meeting?
Failure is humbling. And we (government, academia, industry, and others) have failed to date to find an effective therapy for AD patients. We are looking for new ways to work together to meet this grand challenge.
What are we trying to accomplish?
Our goal is to gear up collaborations that will enable a well-integrated and seamless approach to AD research and drug development.
Toward this end, the NIA hosted a meeting in April of this year: Enabling Partnerships for AD Drug Development. We brought together more than 60 leaders from academia, the NIH, the FDA, foundations, public advocacy groups, and the biotech and pharmaceutical industries.
A series of thought-provoking presentations opened the meeting:
- Stephen Friend of Sage Bionetworks shared his vision for making biomedical research more open source and illustrated how computational challenges can be used to crowdsource innovation. He talked about the need to redefine data sharing if we are to build predictive models of disease, given ever-increasing amounts of human “omic” data.
- Joel Dudley of Mount Sinai Icahn Institute for Genomics and Multiscale Biology illustrated how network biology and translational bioinformatics can inform the selection of therapeutic targets and rational drug repurposing.
- Michael Rogers of NIGMS and Julie Stone of Merck described the emergence of quantitative and systems pharmacology (PDF 1,294K), a model based, data-driven approach to drug development that integrates cell biology, tissue and organ physiology and pharmacology with various bioinformatic and “omic” approaches, and how this approach might inform key steps in drug development.
- Chas Bountra of the Oxford University Structural Genomics Consortium spoke about precompetitive partnerships as tools for knowledge creation and presented a model of a partnership for clinical validation of novel targets that would expand the precompetitive space through phase II trials.
Spirited discussion and breakout sessions followed the talks. Participants explored how these new models of data sharing, translational science, and partnering can be adopted and adapted to AD research and drug development. We hope that these discussions will lead to new collaborations and ultimately new partnerships to accelerate AD therapy development.
Participants saw the meeting as an important source of new connections and opportunities. It was an important program development tool for us as well. Please get in touch with me or my colleagues Laurie Ryan and Larry Refolo if you want more information about the content of the meeting.
How can you learn about NIA meetings?
The best way to find out about NIH meetings in your area of interest is to ask your program officer. There are a number of us who facilitate AD and aging research at the NIA. You can ask me, or my colleagues.
You can also learn about Institute-Sponsored Meetings, Workshops, and Conferences in the thrice yearly National Advisory Council on Aging meeting updates.
Recent NIH meetings involving dementias and AD included Alzheimer's Disease-Related Dementias: Research Challenges and Opportunities, and Advancing Treatments for Alzheimer’s Disease in Individuals with Down Syndrome.
Have I answered all of your questions? Please join me in a conversation about AD drug development and partnerships in the comments section, below.